Company news

Roche Holding Ltd news in 2025

Roche Holding Ltd's news releases, calls and decks from 2025, newest first.

View company

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

December 22, 2025

Genentech Announces Agreement With U.S. Government

December 19, 2025

Health Canada authorizes TNKase® (tenecteplase) for the treatment of Acute Ischemic Stroke (AIS)

December 17, 2025

Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

December 16, 2025

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU

December 15, 2025

Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

December 11, 2025

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

December 10, 2025

Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

December 9, 2025

European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

December 9, 2025

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

December 8, 2025

Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study

December 8, 2025

Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)

December 2, 2025

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

November 19, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

November 18, 2025

Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche

November 12, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis

November 10, 2025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 5, 2025

Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

November 3, 2025

Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus

November 3, 2025

Roche purchases shares in tender offer for 89bio, Inc

October 30, 2025

Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue

October 29, 2025

Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome

October 28, 2025

Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics

October 27, 2025

Changes to the Roche Enlarged Corporate Executive Committee

October 23, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

October 23, 2025

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

October 20, 2025

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

October 20, 2025

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

October 18, 2025

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

October 17, 2025

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

October 17, 2025

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

October 16, 2025

Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

October 13, 2025

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

October 13, 2025

Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub

October 10, 2025

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

October 7, 2025

Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel

October 6, 2025

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

October 3, 2025

Change in the Roche Board of Directors

October 3, 2025

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 2, 2025

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

October 1, 2025

Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

September 30, 2025

Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

September 24, 2025

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

September 22, 2025

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

September 19, 2025

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

September 18, 2025

89bio, Inc. Announces Agreement to be Acquired by Roche

September 16, 2025

Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

September 16, 2025

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

September 5, 2025

Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

September 4, 2025

Calls in 2025

Decks in 2025